Background: In 2019, 4 patients with borderline resectable-pancreatic ductal adenocarcinoma(BR-PDAC)received neoadjuvant chemotherapy(NAC)with 3 cycles of gemcitabine plus nab-paclitaxel(GnP)over 12 weeks in combination with intestinal care, and subsequently underwent pancreatectomy. Surprisingly, histological response to NAC was Grade 3(viable tumor cells <10%)in 3 out of 4 patients. Aim/subjects: This study aimed to clarify the histopathological findings common to 3 patients with Grade 3 histological response to NAC.
Results: Common histopathological findings were as follows: 1)each tumor bed was extensively replaced by fibrous connective tissues with a high degree of inflammatory cell infiltration, and almost no viable cancer cells were observed; 2)all cancer cells within the perineural space where perineural invasion is usually seen, had undergone cytolysis; 3)tertiary lymphoid structures(TLSs)with germinal centers were found at the periphery of each tumor bed, and many plasma cells were seen adjacent to TLSs; and 4)a lot of tingible body macrophages that phagocytosed apoptotic B cells were present around germinal center.
Conclusions: NAC with 3 cycles of GnP over 12 weeks in combination with intestinal care elicited a potent antitumor immune response through enhanced germinal center reactions within TLSs.
背景:2019年,4名边界可切除胰腺导管腺癌(BR-PDAC)患者接受了吉西他滨+纳布-紫杉醇(GnP)3个周期、为期12周的新辅助化疗(NAC),并结合肠道护理,随后接受了胰腺切除术。令人惊讶的是,患者对 NAC 的组织学反应为 3 级(肿瘤细胞存活):常见的组织病理学结果如下:1)每个瘤床都被纤维结缔组织广泛取代,并伴有高度的炎性细胞浸润,几乎没有观察到存活的癌细胞;2)通常可见的神经周围侵犯的神经周围间隙内的所有癌细胞都已被细胞溶解;3)在每个瘤床的外围都发现了带有生发中心的三级淋巴结构(TLSs),TLSs 附近可见大量浆细胞;4)在生发中心周围存在大量吞噬凋亡 B 细胞的可定型体巨噬细胞。结论12周内使用3个周期GnP的NAC与肠道护理相结合,可通过增强TLS内的生发中心反应引起有效的抗肿瘤免疫反应。
{"title":"Enhanced Germinal Center Reactions Within Tertiary Lymphoid Structures Following Neoadjuvant Chemotherapy and Intestinal Care-A Path to Robust Antitumor Immune Response in Borderline Resectable Pancreatic Ductal Adenocarcinoma.","authors":"Tetsuo Ohta, Isamu Makino, Mitsuyoshi Okazaki, Shintaro Yagi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>In 2019, 4 patients with borderline resectable-pancreatic ductal adenocarcinoma(BR-PDAC)received neoadjuvant chemotherapy(NAC)with 3 cycles of gemcitabine plus nab-paclitaxel(GnP)over 12 weeks in combination with intestinal care, and subsequently underwent pancreatectomy. Surprisingly, histological response to NAC was Grade 3(viable tumor cells <10%)in 3 out of 4 patients. Aim/subjects: This study aimed to clarify the histopathological findings common to 3 patients with Grade 3 histological response to NAC.</p><p><strong>Results: </strong>Common histopathological findings were as follows: 1)each tumor bed was extensively replaced by fibrous connective tissues with a high degree of inflammatory cell infiltration, and almost no viable cancer cells were observed; 2)all cancer cells within the perineural space where perineural invasion is usually seen, had undergone cytolysis; 3)tertiary lymphoid structures(TLSs)with germinal centers were found at the periphery of each tumor bed, and many plasma cells were seen adjacent to TLSs; and 4)a lot of tingible body macrophages that phagocytosed apoptotic B cells were present around germinal center.</p><p><strong>Conclusions: </strong>NAC with 3 cycles of GnP over 12 weeks in combination with intestinal care elicited a potent antitumor immune response through enhanced germinal center reactions within TLSs.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"1038-1043"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142688751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A 58-year-old man was treated with radical excision for rectal cancer. Pathological findings were pT3N1M0, Stage ⅢB, RAS: mutant, BRAF: mutant, MSS. The patient was followed up without adjuvant chemotherapy. Eight months after surgery, a CT scan showed recurrence of liver metastases, and chemotherapy was started. The patient was started on regorafenib as the fourth-line therapy for multiple liver metastases, distant lymph node metastases, and peritoneal dissemination. Twenty-three days after the first course, he developed severe abdominal pain and visited the emergency department on day 25. Suspecting generalized peritonitis due to perforation of the upper gastrointestinal tract, he was treated with emergency laparotomy and drainage. A perforation was found in the anterior wall of the lower gastrointestinal body and was sutured closed. There were no adverse events, and the patient was discharged on the 21st postoperative day. regorafenib is a multi-kinase inhibitor, and gastrointestinal perforation has been reported as a serious adverse event, although it is rare. We report a case of upper gastrointestinal perforation during regorafenib administration, with some discussion of the literature.
{"title":"[A Case of Upper Gastrointestinal Perforation during Treatment with Regorafenib for Recurrent Rectal Cancer].","authors":"Suzue Yoshizawa, Keisuke Kazama, Kazuki Otani, Itaru Hashimoto, Aya Kato, Yukio Maezawa, Sho Sawazaki, Toru Aoyama, Norio Yukawa, Aya Saito, Yasushi Rino","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 58-year-old man was treated with radical excision for rectal cancer. Pathological findings were pT3N1M0, Stage ⅢB, RAS: mutant, BRAF: mutant, MSS. The patient was followed up without adjuvant chemotherapy. Eight months after surgery, a CT scan showed recurrence of liver metastases, and chemotherapy was started. The patient was started on regorafenib as the fourth-line therapy for multiple liver metastases, distant lymph node metastases, and peritoneal dissemination. Twenty-three days after the first course, he developed severe abdominal pain and visited the emergency department on day 25. Suspecting generalized peritonitis due to perforation of the upper gastrointestinal tract, he was treated with emergency laparotomy and drainage. A perforation was found in the anterior wall of the lower gastrointestinal body and was sutured closed. There were no adverse events, and the patient was discharged on the 21st postoperative day. regorafenib is a multi-kinase inhibitor, and gastrointestinal perforation has been reported as a serious adverse event, although it is rare. We report a case of upper gastrointestinal perforation during regorafenib administration, with some discussion of the literature.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"1080-1082"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
An 80-year-old woman presented to our hospital complaining of nausea and abdominal distention. An abdominal computed tomography scan revealed wall thickening of the small intestine, a dilated oral intestinal tract, swollen intra-abdominal lymph nodes, and splenomegaly. Moreover, the soluble interleukin-2 receptor level was increased at 2,120 U/mL. Accordingly, we diagnosed the patient with a small bowel obstruction due to malignant lymphoma of the small intestine, for which we performed a laparoscopy-assisted partial resection of the small intestine after decompression. The resected specimen was pathologically diagnosed as diffuse large B-cell lymphoma. The patient's general condition recovered rapidly after laparoscopic surgery, and her clinical course proceeded smoothly to the initiation of chemotherapy(R-CHOP)at the Department of Hematology. The tumor remains in remission now. Here, we report a case of laparoscopic surgery for malignant lymphoma of the small intestine that caused bowel obstruction due to luminal narrowing along with a relevant literature review.
一名 80 岁的妇女来到我院就诊,主诉恶心和腹胀。腹部计算机断层扫描显示小肠壁增厚、口腔肠道扩张、腹腔内淋巴结肿大和脾脏肿大。此外,可溶性白细胞介素-2 受体水平升高至 2 120 U/mL。因此,我们诊断患者为小肠恶性淋巴瘤导致的小肠梗阻,并在减压后为其实施了腹腔镜辅助下的小肠部分切除术。切除标本经病理诊断为弥漫大 B 细胞淋巴瘤。腹腔镜手术后,患者全身情况迅速恢复,临床过程顺利,并在血液科开始接受化疗(R-CHOP)。目前肿瘤仍处于缓解期。在此,我们报告了一例腹腔镜手术治疗小肠恶性淋巴瘤的病例,该手术因管腔狭窄而导致肠梗阻,并对相关文献进行了综述。
{"title":"[A Case of Laparoscopic Surgery for Malignant Lymphoma of the Small Intestine with Bowel Obstruction].","authors":"Naohiko Otsuka, Ouki Yasui, Wataru Iwasaki, Yujiro Kato, Teiji Takahashi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An 80-year-old woman presented to our hospital complaining of nausea and abdominal distention. An abdominal computed tomography scan revealed wall thickening of the small intestine, a dilated oral intestinal tract, swollen intra-abdominal lymph nodes, and splenomegaly. Moreover, the soluble interleukin-2 receptor level was increased at 2,120 U/mL. Accordingly, we diagnosed the patient with a small bowel obstruction due to malignant lymphoma of the small intestine, for which we performed a laparoscopy-assisted partial resection of the small intestine after decompression. The resected specimen was pathologically diagnosed as diffuse large B-cell lymphoma. The patient's general condition recovered rapidly after laparoscopic surgery, and her clinical course proceeded smoothly to the initiation of chemotherapy(R-CHOP)at the Department of Hematology. The tumor remains in remission now. Here, we report a case of laparoscopic surgery for malignant lymphoma of the small intestine that caused bowel obstruction due to luminal narrowing along with a relevant literature review.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"1017-1019"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A 77-year-old man underwent a right hemihepatectomy for hepatocellular carcinoma in 2002. The patient remained alive without recurrence for 17 years after surgery. In September 2019, he was diagnosed with a tumor in the lower lobe of the right lung by follow-up CT. A partial right lung resection was performed in February 2020. Histological and immunohistochemical staining confirmed the recurrence of a previous hepatocellular carcinoma. Late lung cancer recurrence after radical hepatectomy is rare. Here, we report a case of hepatocellular carcinoma relapse in the lungs 17 years after liver resection.
{"title":"[A Case of Hepatocellular Carcinoma Relapse in the Lungs 17 Years after Liver Resection].","authors":"Ouki Yasui, Ikuo Matsuzaki, Masayo Murakami, Hiroshi Nanjo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 77-year-old man underwent a right hemihepatectomy for hepatocellular carcinoma in 2002. The patient remained alive without recurrence for 17 years after surgery. In September 2019, he was diagnosed with a tumor in the lower lobe of the right lung by follow-up CT. A partial right lung resection was performed in February 2020. Histological and immunohistochemical staining confirmed the recurrence of a previous hepatocellular carcinoma. Late lung cancer recurrence after radical hepatectomy is rare. Here, we report a case of hepatocellular carcinoma relapse in the lungs 17 years after liver resection.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"1021-1024"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We report 2 cases of early breast cancer treated with adjuvant S-1 plus endocrine therapy. In case 1, a 70-year-old woman was diagnosed with right breast cancer and underwent partial mastectomy. The histopathological diagnosis was invasive ductal carcinoma(solid type), positive for estrogen receptor(ER)and progesterone receptor(PgR), negative for HER2/neu. The Ki-67 labeling index was 14%. The diameter of invasion was 27 mm, no lymph node metastasis was observed, and we confirmed the diagnosis as pT2N0M0, Stage ⅡA. A venous invasion was observed and the histological grade was Ⅱ. In case 2, a 53-year-old woman was diagnosed with left breast cancer and underwent lumpectomy. The histopathological findings showed a solid-tubular carcinoma, characterized by ER-positive, PgR-positive, HER2-negative. The Ki-67 labeling index was 24%. The tumor had an invasion of 20 mm and was diagnosed as Stage Ⅰ early-stage cancer, but there were some venous invasions and the histological grade was Ⅲ. We judged that both patients were at intermediate risk of recurrence and administered S-1 in addition to endocrine therapy. Even in cases without axillary lymph node metastasis, this combination of S-1 with endocrine therapy was considered to be a useful treatment option if the criteria of the POTENT trial were met.
{"title":"[Early Breast Cancer Treated with Adjuvant S-1 plus Endocrine Therapy-A Report of Two Cases].","authors":"Keita Adachi, Junko Nagae, Hitomi Kubota, Shuhei Suzuki, Tomohiro Hirano, Natsuki Saigusa, Takuo Henmi, Hisao Yagishita, Hitoshi Tsuda, Kenichi Sakurai","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We report 2 cases of early breast cancer treated with adjuvant S-1 plus endocrine therapy. In case 1, a 70-year-old woman was diagnosed with right breast cancer and underwent partial mastectomy. The histopathological diagnosis was invasive ductal carcinoma(solid type), positive for estrogen receptor(ER)and progesterone receptor(PgR), negative for HER2/neu. The Ki-67 labeling index was 14%. The diameter of invasion was 27 mm, no lymph node metastasis was observed, and we confirmed the diagnosis as pT2N0M0, Stage ⅡA. A venous invasion was observed and the histological grade was Ⅱ. In case 2, a 53-year-old woman was diagnosed with left breast cancer and underwent lumpectomy. The histopathological findings showed a solid-tubular carcinoma, characterized by ER-positive, PgR-positive, HER2-negative. The Ki-67 labeling index was 24%. The tumor had an invasion of 20 mm and was diagnosed as Stage Ⅰ early-stage cancer, but there were some venous invasions and the histological grade was Ⅲ. We judged that both patients were at intermediate risk of recurrence and administered S-1 in addition to endocrine therapy. Even in cases without axillary lymph node metastasis, this combination of S-1 with endocrine therapy was considered to be a useful treatment option if the criteria of the POTENT trial were met.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"1065-1067"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Ⅰ. The Trend of Precision Medicine in Treatment of Hepatocellular Carcinoma].","authors":"Junichi Arita, Shuhei Chida, Misato Horie, Naohiko Otsuka, Kimihiko Sato, Shinichiro Atsumi, Yasuhiko Nakagawa, Go Watanabe","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"985-988"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We experienced cases of malnutrition and vitamin B1 deficiency after gastrointestinal cancer surgery, but they had a good course after vitamin B1 administration. Case 1 is a woman in her 70s who underwent laparoscopic distal gastrectomy for gastric cancer 2 months ago. While under outpatient observation, she was found collapsed at home and urgently brought to the hospital. She lost 3 kg of body weight in 2 weeks and was able to take in oral intake by giving fluids for malnutrition, but was unable to sit up unaided. During the course of hospitalization, vitamin B1 deficiency was reported, and vitamin B1 administration was started, which enabled her to walk independently. Case 2 is a man in her 50s who underwent video-assisted thoracic esophagectomy for esophageal cancer approximately 1 year ago. He was urgently brought to the hospital due to decreased oral intake due to alcohol dependence. 17.1 kg/m2 BMI, malnutrition, 67/40 mmHg blood pressure, and decreased left ventricular septal wall motion were observed. Vitamin B1 deficiency due to alcohol dependence was suspected, so vitamin B1 administration was started, and blood pressure increased within a few hours.
{"title":"[Cases of Malnutrition and Vitamin B1 Deficiency after Gastrointestinal Cancer Surgery].","authors":"Junji Kawada, Minami Maruyama, Yoshitaka Okauchi, Tomonori Nomura, Yuji Ikeda, Manatsu Mizuno, Satoshi Eguchi, Yoshiki Taniguchi, Hiromitsu Hoshino, Shinya Yamashita, Hitoshi Mizuno, Yo Sasaki","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We experienced cases of malnutrition and vitamin B1 deficiency after gastrointestinal cancer surgery, but they had a good course after vitamin B1 administration. Case 1 is a woman in her 70s who underwent laparoscopic distal gastrectomy for gastric cancer 2 months ago. While under outpatient observation, she was found collapsed at home and urgently brought to the hospital. She lost 3 kg of body weight in 2 weeks and was able to take in oral intake by giving fluids for malnutrition, but was unable to sit up unaided. During the course of hospitalization, vitamin B1 deficiency was reported, and vitamin B1 administration was started, which enabled her to walk independently. Case 2 is a man in her 50s who underwent video-assisted thoracic esophagectomy for esophageal cancer approximately 1 year ago. He was urgently brought to the hospital due to decreased oral intake due to alcohol dependence. 17.1 kg/m2 BMI, malnutrition, 67/40 mmHg blood pressure, and decreased left ventricular septal wall motion were observed. Vitamin B1 deficiency due to alcohol dependence was suspected, so vitamin B1 administration was started, and blood pressure increased within a few hours.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"1074-1076"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Online medicine has become more common since the COVID-19 pandemic, but there are few cases of hospitals introducing online genetic counseling(OGC)in Japan. We introduced the online medical consultation application at 2 medical institutions for OGC. Genetic counseling for hereditary tumors will need to be broadened and implemented widely. Using the application makes it easy to make and complete reservations. OGC, which can reduce the time and space burden on clients, is a promising option of genetic counseling. It is hoped that OGC will become more widespread as a form of genetic medicine in the future, so that a limited number of genetic specialists can respond to a wide range of needs. In order to increase the number of users in the future, it is necessary to 1)raise awareness among the general public through public relations activities, and 2)collaborate with medical facilities that do not have specialized outpatient clinics for hereditary tumors.
{"title":"[Introduction of Online Genetic Counseling for Hereditary Tumors Using an Online Medical Consultation Application].","authors":"Takeshi Nakajima","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Online medicine has become more common since the COVID-19 pandemic, but there are few cases of hospitals introducing online genetic counseling(OGC)in Japan. We introduced the online medical consultation application at 2 medical institutions for OGC. Genetic counseling for hereditary tumors will need to be broadened and implemented widely. Using the application makes it easy to make and complete reservations. OGC, which can reduce the time and space burden on clients, is a promising option of genetic counseling. It is hoped that OGC will become more widespread as a form of genetic medicine in the future, so that a limited number of genetic specialists can respond to a wide range of needs. In order to increase the number of users in the future, it is necessary to 1)raise awareness among the general public through public relations activities, and 2)collaborate with medical facilities that do not have specialized outpatient clinics for hereditary tumors.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"977-981"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Liver, Pancreas, Biliary Tract Cancer The Recent Progress and Clinical Implications of Tumor Biomarkers in Hepatobiliary Pancreatic Malignancies].","authors":"Masaru Miyazaki","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"982-984"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}